SHORT REPORT
RHEUMATOLOGY

Effect of short-interval rituximab and high-dose corticosteroids on kidney function in systemic sclerosis: Long-term experience of a single centre

Balazs Odler¹ | Carina Hebesberger¹ | Lukas Hoesfechner¹ | Gudrun Pregartner² | Paul Gressenberger³ | Philipp Jud³ | Sabine Zenz⁴ | Kathrin Eller¹ | Alexander R. Rosenkranz¹ | Florentine Moazedi-Fuerst⁴

¹Division of Nephrology, Department of Internal Medicine, Medical University of Graz, Graz, Austria
²Institute for Medical Informatics, Statistics and Documentation, Medical University of Graz, Graz, Austria
³Division of Angiology, Department of Internal Medicine, Medical University of Graz, Graz, Austria
⁴Division of Rheumatology and Immunology, Department of Internal Medicine, Medical University of Graz, Graz, Austria

Abstract

Introduction: Scleroderma renal crisis (SRC) is a rare but one of the most recognised complications of systemic sclerosis (SSc). Corticosteroid (CS) use has been considered as a major risk factor for SRC. Several studies reported the efficacy of rituximab (RTX) with an acceptable safety profile in SSc. However, data on the long-term effect of high-dose CS concomitant to RTX on kidney function are lacking.

Methods: We retrospectively analysed SSc patients (n = 35) treated with a lower dosage and short-interval RTX and concomitant high-dose CS at the Department of Internal Medicine at the Medical University of Graz between 2010 and 2019. The kidney function was assessed using the estimated glomerular filtration rate (eGFR) at every RTX admission. The annual decline of kidney function was evaluated by linear mixed model analysis.

Results: At the RTX initiation, one patient had a decreased kidney function indicated by eGFR < 60 mL/min/1.73 m² (median: 96 mL/min/1.73 m²; interquartile range (IQR): 43-136). Patients received RTX and complementary high-dose CS for a median follow-up time of 3.4 years (range 0.6-9.5). A linear mixed model analysis with the patient as random effect and time from first RTX as fixed effect estimated an annual decline of 1.98 mL/min/1.73 m² of the eGFR (95% confidence interval: [-2.24, -1.72]; P <.001). During the follow-up period, no patient experienced SRC or a significant drop in kidney function.

Conclusions: A regular, high-dose CS given contemporary to RTX seems to be a safe option for kidney function in patients with SSc. Our findings provide additional knowledge in risk evaluation and planning of individualised therapies or designing clinical studies using RTX.
INTRODUCTION

Systemic sclerosis (SSc) is an immune-mediated multiorgan disease characterised by autoimmunity, inflammation, vasculopathy and progressive fibrosis. Renal involvement associated with vasculopathy is commonly seen in SSc, which usually shows a benign course. In contrast, scleroderma renal crisis (SRC) is rare but one of the most recognised complications of SSc. Despite distinct improvements in therapy, a significant proportion of patients with SRC develop end-stage renal disease (ESRD), and the survival remains poor. Several risk factors are associated with SRC, including the recent use of corticosteroids (CS).

In the last years, several studies, including randomised, controlled trials (RCTs) and open-label prospective studies, reported the efficacy of rituximab (RTX), and RTX biosimilar with an acceptable safety profile in SSc. However, since some patients may experience infusion-related adverse reactions such as antibody-mediated hypersensitivity and non-antibody-mediated reactions, a premedication protocol with substantial CS use is not avoidable. According to the European League Against Rheumatism (EULAR) recommendations, SSc patients treated with CS should be carefully monitored for the development of SRC. We previously reported a case series of SSc patients successfully treated with a lower dosage and short-interval RTX regime. These data might favour a short interval application as a treatment of choice in SSc, but data on the safety of this protocol on kidney function regarding the frequent use of high-dose CS are lacking. Therefore, we aimed to describe the long-term effect and safety of high-dose CS on kidney function obtained longitudinally in SSc patients who received a short-interval RTX regime.

METHODS

Study design and patients

We retrospectively analysed SSc patients treated with RTX at the Department of Internal Medicine at the Medical University of Graz between 2010 and 2019. Thirty-nine patients received a lower dosage and short-interval RTX 500 mg on day 0 and day 14, and then twice every three months. Intravenous systemic prednisone at a fixed 100 mg dose was administrated 30 minutes before every RTX application. We ultimately analysed 35 out of 39 patients because, in the remaining patients, we were unable to obtain the initial kidney function parameters (n = 2), or the patient had SRC and/or was on haemodialysis (n = 2) before RTX treatment. The kidney function using the estimated glomerular filtration rate (eGFR assessed by CKD-EPI formula) was assessed at every RTX admission. The last observation occurred when the SRC occurred, the patient died, the patient left the practice, or the study ended in June 2020. The study protocol was reviewed and approved by an independent ethics committee of the local institution (Ethics Committee of the Medical University of Graz – EK-Numbers: 31-171 ex 18/19 and 24-184 ex 11/12).

RESULTS

Table 1 gives the characteristics of the SSc patients at the start of RTX, SRC risk factors, RTX indications, and the number of therapy cycles. Most of the 35 patients had at least one SRC risk factor at the time of RTX initiation: 8 (23%) were male, 28 (80%) had diffuse cutaneous SSc, 11 (31%) a modified Rodnan skin score (mRSS) >20, 2 (6%) cardiac involvement, and 8 (23%) used angiotensin-converting enzyme inhibitors (ACEi). Anti-RNA-Polymerase III measurement was available only in 10 patients, and none was positive.

The median number of RTX cycles was 21, and thus the median cumulative dose was 2100 mg. The lowest cumulative dose given was 500 mg (5 cycles), while the highest cumulative dose was 5100 mg (51 cycles) among the study patients. Five patients received antihypertensive agents newly prescribed during the follow-up period. However, in only two cases was development of arterial hypertension was observed, and an ACE-inhibitor with beta-blocker or a CCB was prescribed. CCBs have been prescribed to prevent peripheral small vessel changes in the other three cases.

At the time of RTX initiation, one patient had a decreased kidney function indicated by eGFR < 60 mL/min/1.73 m². The median eGFR was 96 mL/min/1.73 m² (interquartile range [IQR]: 43-136). Patients received RTX and complementary high-dose CS for a median follow-up time of 3.4 years (range 0.6-9.5). A linear mixed model analysis with the patient as random effect and time from...
TABLE 1 Clinical characteristics of the study population at the time of rituximab initiation

| Characteristic                        | Value         |
|--------------------------------------|---------------|
| Total number of patients, n          | 35            |
| Age, y                               | 52 (29-71)    |
| Female, n (%)                        | 27 (77)       |
| BMI (kg/m²)                          | 23.5 (17.4-45.9) |
| SSc-related data                     |               |
| IcSSc, n (%)                         | 7 (20)        |
| dcSSc, n (%)                         | 28 (80)       |
| MCTD, n (%)                          | 5 (14)        |
| mRSS                                 | 16 (3-39)     |
| Antibody profile                     |               |
| ANA, n (%)                           | 34 (97)       |
| ENA, n (%)                           | 23 (66)       |
| CENP-B, n (%)                        | 3 (9)         |
| Anti-Scl-70, n (%)                   | 19 (54)       |
| Anti-U1-RNP, n (%)                   | 3 (9)         |
| Ro, n (%)                            | 7 (20)        |
| Kidney function                      |               |
| Creatinine (mg/dL)                   | 0.70 (0.48-1.91) |
| eGFR (mL/min/1.73 m²)                | 96 (43-136)   |
| eGFR < 60 mL/min/1.73 m², n (%)      | 1 (3)         |
| Proteinuria ≥ 2+ by dipstick         | 0 (0)         |
| RTX cycles, steroid dose, and indication |         |
| RTX cycles                           | 21 (5-51)     |
| Cumulative steroid dose (mg)<sup>a</sup> | 2100 (500-5100) |
| Skin involvement, n (%)              | 14 (40)       |
| Lung involvement, n (%)              | 26 (74)       |
| Esophageal involvement, n (%)        | 5 (14)        |
| Heart involvement, n (%)             | 2 (6)         |
| Muscle involvement, n (%)            | 1 (3)         |
| Joint involvement, n (%)             | 2 (6)         |
| Antihypertensive therapy             |               |
| ACEI, n (%)                          | 8 (23)        |
| ARB, n (%)                           | 0 (0)         |
| CCB, n (%)                           | 7 (20)        |
| Beta-blocker, n (%)                  | 3 (9)         |

| Note: Continuous variables are expressed as median (interquartile range, q1-q3), categorical variables as n (%). Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ANA, antinuclear antibody; ARB, angiotensin receptor blocker; AZA, azathioprine; BMI, body mass index; CCB, calcium channel blocker; CENP-B, centromere protein B; CS, corticosteroid; dc, diffuse cutaneous; eGFR, estimated glomerular filtration rate; ENA, extractable nuclear antigen; lc, limited cutaneous; MCTD, mixed connective tissue disease; mRSS, modified Rodnan skin score; RTX, rituximab; SRC, scleroderma renal crisis; SSc, systemic sclerosis. |

First RTX as fixed effect estimated an annual decline of 1.98 mL/min/1.73 m² of the eGFR (95% confidence interval: [-2.24, -1.72]; P < .001; Figure 1). At the end of the observation period, the median eGFR was 88.4 mL/min/1.73 m² (IQR: 76.7-99.4), while the serum creatinine was 0.8 mg/dL (IQR: 0.6-0.9). During the follow-up period, no patient experienced SRC or a significant drop in kidney function.

4 | DISCUSSION

In this study investigating SSc patients who received a high dose of systemic prednisone given to a short-interval RTX regime, we observed no SRC or significant drop in kidney function during the observation period.

SRC is a potentially life-threatening complication of SSc. So far, CS use is considered as a significant risk factor for SRC irrespective of whether medium-, high, or prolonged use of low doses are applied. In some clinical situations, the usefulness of CS has been considered, particularly in patients with very early disease and in those with initial organ involvement. Moreover, glucocorticoids remain a part of the therapeutic strategy in SSc patients with musculoskeletal involvement. Nevertheless, the need for CS therapy in SSc patients should be carefully considered, and individualised risk stratification in every patient is required. Since RTX is often used in the management of SSc, particularly in patients with interstitial lung disease, inflammatory arthritis, skin involvement, and overlap syndrome, adverse events such as SRC due to contemporary CS use must be considered. Previously, RTX regimes applied in the different studies used a subsequently lower total CS dose during a shorter median follow-up time than our protocol. Because CS given in higher doses has been extensively described as associated with higher SRC incidence and outcome, a close follow-up of kidney function in our patients was essential. Importantly, in our cohort, 80% of the patients had diffuse cutaneous disease subset, and most of them had at least one SRC risk factor. However, no SRC occurred, and only in two cases were a newly developed arterial hypertension observed that necessitated antihypertensive therapy initiation.

The control of blood pressure in SSc patients is challenging. In our cohort, most of the patients received ACEI due to previously diagnosed arterial hypertension at baseline. Despite the clear benefit of ACEI in SRC and certain patient populations, including those with chronic kidney disease (CKD), data on their effect on preventing SRC and the development of CKD in patients with SSc are controversial. In an early study that investigates patients with SSc with proteinuria, ACEI initiation led to decreased proteinuria. In contrast, recent publications concluded that ACEI might represent an independent risk factor for the development of SRC, particularly in those with proteinuria. Therefore, the use and safety of ACEI should be considered carefully in SSc patients receiving CS, and studies on different antihypertensive agents should focus in more detail on this population.

Despite the smaller number of patients involved in our study, our data with nearly fully administrated kidney function during RTX therapy could demonstrate a safe option for using a frequent, high-dose CS given to RTX. Notably, patients receiving RTX who have severe internal organ involvement or poor prognostic features and are...
most likely to receive additional CS or those treated with potentially nephrotoxic medications should be more carefully followed for SRC. Controlled trials are needed to confirm the beneficial effects of a short interval and low-dosage RTX regime on various organ involvements in patients with SSC. Here, the possible negative impact of the frequent use of high-dose CS must be implemented by all physicians deciding for RTX. Nevertheless, in this analysis, we demonstrated that this regime using a regular, high-dose CS given contemporary to RTX seems to be a safe option for kidney function in patients with SSC. Our findings provide additional knowledge in risk evaluation and planning individualised therapies or designing clinical studies using RTX. Despite these results, we recommend continuing the tight control of kidney function and blood pressure during RTX application in SSC.

ACKNOWLEDGMENTS
THE study group is greatly indebted to all the nurses at the day hospital at the Department of Internal Medicine, Medical University of Graz.

DISCLOSURE
The authors declare no conflicts of interest.

DATA AVAILABILITY STATEMENT
The datasets generated and/or analysed during the current study are available from the corresponding author on reasonable request.

ORCID
Balazs Odler https://orcid.org/0000-0002-8176-5202

REFERENCES
1. Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017;390: 1685-1699.
2. Woodworth TG, Suliman YA, Li W, Furst DE, Clements P. Scleroderma renal crisis and renal involvement in systemic sclerosis. Nat Rev Nephrol. 2016;12:678-691.
3. Hruskova Z, Pippias M, Stel VS, et al. Characteristics and outcomes of patients with systemic sclerosis (scleroderma) requiring renal replacement therapy in Europe: results from ERA-EDTA registry. Am J Kidney Dis. 2018;73:184-193.
4. Jordan S, Distler JHW, Maurer B, et al. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis. 2015;74:1188-1194.
5. Elhai M, Boubaya M, Distler O, et al. Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study. Ann Rheum Dis. 2019;78: 979-987.
6. Kowal-Bielecka O, Fransen J, Avouac J, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017;76:1327-1339.
7. Sircar G, Goswami RP, Sircar D, Ghosh A, Ghosh P. Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease open-label, randomized, controlled trial. Rheumatology (Oxford). 2018;57:2106-2113.
8. Campochiaro C, De Luca G, Lazzaroni MG, et al. Safety and efficacy of rituximab biosimilar (CT-P10) in systemic sclerosis: an Italian multicentre study. Rheumatology. 2020;59:3731-3736.
9. Moazed-Fuerst FC, Kielhauser SM, Bodo K, Graninger WB. Dosage of rituximab in systemic sclerosis: 2-year results of five cases. Clin Exp Dermatol. 2015;40:211-212.
10. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604-612.
11. Toescu SM, Mansell A, Dinneen E, Persey M. Steroid-induced scleroderma renal crisis in an at-risk patient. BMJ Case Rep. 2014;2014:bcr2014206675.
12. Blagojevic J, Legendre P, Matucci-Cerinic M, Mouthon L. Is there today a place for corticosteroids in the treatment of scleroderma? Autoimmun Rev. 2019;18:102403.
13. Fernández-Codina A, Walker KM, Pope JE. Scleroderma Algorithm Group. Treatment algorithms for systemic sclerosis according to experts. Arthritis Rheumatol. 2018;70:1820-1828.
14. van den Hombergh WMT, Kersten BE, Knaapen-Hans HKA, et al. Hit hard and early: analysing the effects of high-dose methylprednisolone on nailfold capillary changes and biomarkers in very early systemic sclerosis: study protocol for a 12-week randomised controlled trial. Trials. 2018;19:449.
15. Steen VD, Medsger TA Jr. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. *Arthritis Rheum*. 1998;41:1613-1619.

16. Bütikofer L, Varisco PA, Distler O, et al. ACE inhibitors in SSc patients display a risk factor for scleroderma renal crisis – a EUSTAR analysis. *Arthritis Res Ther*. 2020;22:59.

17. Xie X, Liu Y, Perkovic V, et al. Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a Bayesian network meta-analysis of randomized clinical trials. *Am J Kidney Dis*. 2016;67:728-741.

18. Schuster J, Moinzadeh P, Kurschat C, et al. Proteinuria in systemic sclerosis: reversal by ACE inhibition. *Rheumatol Int*. 2013;33:2225-2230.

19. Gordon SM, Hughes JB, Nee R, et al. Systemic sclerosis medications and risk of scleroderma renal crisis. *BMC Nephrol*. 2019;20:279.

---

**How to cite this article:** Odler B, Hebesberger C, Hoeflechner L, et al. Effect of short-interval rituximab and high-dose corticosteroids on kidney function in systemic sclerosis: Long-term experience of a single centre. *Int J Clin Pract*. 2021;75:e14069. [https://doi.org/10.1111/ijcp.14069](https://doi.org/10.1111/ijcp.14069)